Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

被引：0
|
作者：
Kaklamani, Virginia G.
Bardia, Aditya
Aftimos, Philippe Georges
Cortes, Javier
Lu, Janice M.
Neven, Patrick
Streich, Guillermo
Montero, Alberto J.
Forget, Frederic
Mouret-Reynier, Marie-Ange
Sohn, Joohyuk
Taylor, Donatienne
Harnden, Kathleen Kiernan
Khong, Hung T.
Kocsis, Judit
Dalenc, Florence
Dillon, Patrick Michael
Tonini, Giulia
Grzegorzewski, Kris
Bidard, Francois-Clement
机构：
[1] Univ Texas Hlth Sci Ctr, Houston, TX USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[4] Quironsalud Grp, Int Breast Canc Ctr, Barcelona, Spain
[5] Univ Europea Madrid, Madrid, Spain
[6] Univ Southern Calif, Los Angeles, CA USA
[7] Univ Ziekenhuizen UZ, Leuven Canc Inst, Leuven, Belgium
[8] Ctr Med Austral, Buenos Aires, Argentina
[9] Case Western Reserve Univ, Cleveland, OH USA
[10] Seidman Canc Ctr, UH, Cleveland, OH USA
[11] Ctr Hosp Ardenne, Site Libramont, Libramont, Belgium
[12] Ctr Jean Perrin, Clermont Ferrand, France
[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[14] Univ Catholic Louvain, CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium
[15] Inova Schar Canc Ctr, Fairfax, VA USA
[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[17] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary
[18] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France
[19] Univ Virginia Hlth Syst, Charlottesville, VA USA
[20] Menarini Grp, Florence, Italy
[21] Menarini Grp, Stemline Therapeut, New York, NY USA
[22] Inst Curie, Paris, France
[23] Inst Curie, St Cloud, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1100
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer
    Abramson, V.
    Linden, H. M.
    Crew, K.
    Mortimer, J.
    Alidzanovic, J.
    Nangia, J.
    Layman, R.
    Vranjes, Z. J.
    Andric, Z.
    Milovic-Kovacevic, M.
    Trifunovic, J.
    Karchmit, Y.
    Suarez, J.
    Suster, M.
    Ptaszynski, M.
    Chalasani, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S619 - S619
  • [22] Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2-locally advanced or metastatic breast cancer (ABC)
    Dees, E. C.
    Aftimos, P. G.
    van Oordt, C. W. Menke-van der Houven
    De Vries, E. G. E.
    Neven, P.
    Pegram, M. D.
    Iqbal, R.
    Boers, J.
    Xiao, J.
    Sipes, C.
    Li, C.
    Sorrentino, J. A.
    Malik, R.
    Beelen, A. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 121 - +
  • [23] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
    Dickler, Maura N.
    Villanueva, Rafael
    Fidalgo, Jose Alejandro Perez
    Mayer, Ingrid A.
    Boni, Valentina
    Winer, Eric P.
    Hamilton, Erika P.
    Bellet, Meritxell
    Urruticoechea, Ander
    Gonzalez-Martin, Antonio
    Cortes, Javier
    Martin, Miguel
    Giltnane, Jennifer
    Gates, Mary
    Cheeti, Sravanthi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori S.
    Spoerke, Jill M.
    Metcalfe, Ciara
    Liu, Lichuan
    Li, Robert
    Morley, Roland
    McCurry, Ursula
    Chan, Iris T.
    Mueller, Lars
    Milan, Sandra
    Lauchle, Jennifer
    Humke, Eric W.
    Bardia, Aditya
    CANCER RESEARCH, 2018, 78 (04)
  • [24] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
    Kaklamani, Virginia
    Bardia, Aditya
    Wilks, Sharon
    Weise, Amy
    Richards, Donald
    Harb, Wael
    Osborne, Cynthia
    Wesolowski, Robert
    Karuturi, Meghan
    Conkling, Paul
    Bagley, Rebecca
    Jung, JungAh
    Bihani, Teeru
    Conlan, Maureen
    Kabos, Peter
    CANCER RESEARCH, 2020, 80 (04)
  • [26] A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer
    Keogh, G. P.
    Papish, S.
    Piskorski, W.
    Ulanska, M.
    Jackson, B.
    Suster, M.
    Ptaszynski, M.
    Mina, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S618 - S619
  • [27] Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer
    Aftimos, Philippe
    Maglakelidze, Marina
    Glaudemans, Andor W. J. M.
    Hamilton, Erika
    Chap, Linnea
    de Vries, Elisabeth
    van Oordt, Catharina Willemien Menke-van der Houven
    Jager, Agnes
    Dees, E. Claire
    Cristofanilli, Massimo
    Pegram, Mark
    Ulahannan, Susanna
    Neven, Patrick
    Bulat, Iurie
    Rai, Ruhi
    Tao, Wenli
    Jain, Sarika
    Beelen, Andrew P.
    Sorrentino, Jessica A.
    CANCER RESEARCH, 2021, 81 (04)
  • [28] Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2-breast cancer
    Bardia, Aditya
    Dickler, Maura N.
    Mayer, Ingrid A.
    Winer, Eric P.
    Mahmood, Umar
    Ulaner, Gary
    Manning, H. Charles
    Rix, Peter
    Hager, Jeffrey H.
    Roychowdhury, Debasish
    Maneval, Edna Chow
    Arteaga, Carlos L.
    Baselga, Jose
    CANCER RESEARCH, 2015, 75
  • [29] Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
    Campone, Mario
    Bardia, Aditya
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Doroumian, Severine
    Pelekanou, Vasiliki
    Celanovic, Marina
    Linden, Hannah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician's choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2-advanced breast cancer (aBC)
    Tolaney, S. M.
    Chan, A.
    Petrakova, K.
    Delaloge, S.
    Campone, M.
    Iwata, H.
    Peddi, P.
    Kaufman, P. A.
    De Kermadec, E.
    Liu, Q.
    Cohen, P.
    Paux, G.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S634 - S635
12345